MaxCyte has granted Legend Biotech a non-exclusive worldwide license to use MaxCyte's flow electroporation® Technologies and ExPERT™ platforms related to the research, clinical development, and commercialization of cell-based therapeutic products.
In return, MaxCyte will be eligible to receive annual license fees and milestones from Legend Biotech during clinical development and, upon successful commercialization, will be eligible to receive license fees and royalties on net sales of the licensed product. Masu.
“We look forward to supporting Legend Biotech's non-viral engineered cell therapy programs as they expand their portfolio with novel delivery modalities. Our global infrastructure enables us to provide Legend Biotech with technical, scientific and regulatory support to advance their non-viral engineered therapeutic pipeline across all major regions,” said Mahar Masood, President and CEO of MaxCyte.
Legend Biotech CEO Dr. Ying Huang said, “MaxCyte's clinical manufacturing platform, non-viral cell engineering technology, and regulatory expertise will support the development of our product pipeline across a wide range of cell types and modalities.” added. “Our goal is to transform the treatment landscape by creating a broad portfolio of cell therapies that help strengthen patients' immune systems and fight disease.”
